Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

MDV-3100 demonstrates reductions in prostate-specific antigen in phase I/II trial

Nov. 9, 2007

Exelixis has numerous poster presentations at AACR-NCI-EORTC conference

Nov. 9, 2007

Sunesis Pharmaceuticals reports recent data on two lead compounds

Nov. 9, 2007

FDA approves Epeius's phase II registration protocol of Rexin-G for osteosarcoma

Nov. 8, 2007

Recent patents cover new therapeutic agents for cancer

Nov. 8, 2007

huC242-DM4: preclinical studies and a phase I trial

Nov. 8, 2007

Phase III mifamurtide data confirms superior overall survival in osteosarcoma

Nov. 8, 2007

Phase I trial compares daily, twice daily ARRY-543 in patients with solid tumors

Nov. 8, 2007

Sunitinib safe and active in phase II hepatocellular carcinoma study

Nov. 8, 2007

Protox presents positive final data from PRX-302 prostate cancer study

Nov. 7, 2007

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...